X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
Abiraterone and the combination product Abiraterone/Prednisolone are used to treat men with prostate cancer. The 500 mg (mono product) and 500 mg + 5 mg (combination product) tablets will be marketed in Europe by our partners.
Lead Product(s): Abiraterone Acetate,Prednisolone
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2022
Iran Expo
Not Confirmed
Contact SupplierDetails:
SPI-62 is Sparrow’s potent and selective investigational HSD-1 inhibitor, which is investigated in combination with prednisolone for the treatment of polymyalgia rheumatica (PMR) to include a third cohort.
Lead Product(s): SPI-62,Prednisolone
Therapeutic Area: Immunology Product Name: SPI-47
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2023
Details:
SPI-47 combines HSD-1 inhibitor, SPI-62, with an effective glucocorticoid medicine, prednisolone. While prednisolone serves to relieve pain and inflammation, SPI-62 lowers active steroid levels within vital organs, and thereby mitigate the side effects of prednisolone.
Lead Product(s): SPI-62,Prednisolone
Therapeutic Area: Musculoskeletal Product Name: SPI-47
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2023
Details:
SPI-47 combines SPI-62 with an efficacious glucocorticoid medicine to potentially relieve debilitating inflammation with fewer side effects,aims to achieve the same efficacy of glucocorticoids while mitigating their associated toxicities.
Lead Product(s): SPI-62,Prednisolone
Therapeutic Area: Musculoskeletal Product Name: SPI-47
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 09, 2022
Details:
SPI-47 (SPI-62) prevented several CORT adverse effects, demonstrating that by blocking local intracellular glucocorticoid activation with a HSD-1 inhibitor in target tissues, it can mitigate glucocorticoid toxicity.
Lead Product(s): SPI-62,Prednisolone
Therapeutic Area: Musculoskeletal Product Name: SPI-47
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 04, 2022
Details:
Positive results from Phase 3 PROpel trial showed LYNPARZA in combination with abiraterone plus prednisone demonstrated a statistically significant and clinically meaningful improvement in rPFS, versus abiraterone plus prednisone for treatment of patients with mCRPC.
Lead Product(s): Olaparib,Abiraterone Acetate,Prednisolone
Therapeutic Area: Oncology Product Name: Lynparza
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
